Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05206864 Active, not recruiting - Healthy Clinical Trials

Food Trial to Evaluate the Safety and Tolerability of SBD111 in Health Adults

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of the trial is to determine if the synbiotic (prebiotic and probiotic), provided twice daily (capsule) is safe and tolerable in healthy adults.

NCT ID: NCT05155995 Active, not recruiting - Healthy Clinical Trials

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers

Start date: October 21, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2001 and co-administration of each component in fasting and fed conditions respectively in healthy volunteers.

NCT ID: NCT05151146 Active, not recruiting - Healthy Clinical Trials

A Phase 1 Study of ANJ900 Chinese Healthy Subjects

Start date: October 15, 2021
Phase: Phase 1
Study type: Interventional

This will be a Phase 1, randomised, open label, 3 way crossover study in healthy male and female Chinese subjects. Subjects will participate in 3 treatment periods and will be randomised in a 1:1:1 ratio to 1 of 3 treatment sequences. There will be a washout period of 7 days between doses.

NCT ID: NCT05138861 Active, not recruiting - Healthy Clinical Trials

A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

Start date: February 9, 2021
Phase: Phase 1
Study type: Interventional

Pharmacokinetic Study to Evaluate the Whole Blood Pharmacokinetics of TP-03 Following Six Week Topical Ocular Administration.

NCT ID: NCT05117437 Active, not recruiting - Healthy Clinical Trials

The Effect Of Anaerobic Exercise On Bone Morphogenetic Protein 9

Start date: December 3, 2020
Phase:
Study type: Observational

Bone morphogenetic protein (BMP) 9 from the BMP family has an important role in the remodeling of bone and cartilage. Due to these features, BMP9 can play an important role in especially anaerobic exercise training adaptations. However, the role of anaerobic exercise in these effects is still unclear. The aim of this study is to investigate the role of BMP9 on the effects of acute and chronic anaerobic exercise on bone metabolism markers. Postprandial venous blood samples were taken pre- and post- acute YOYO intermittent recovery test (level 1) in 40 trained male athletes aged 18-35 who did anaerobic sports (such as basketball, volleyball and handball) and 41 sedentary volunteers aged 18-35. Serum BMP9, as markers of bone formation and resorption; alkaline phosphatase (ALP), C-terminal telopeptide of type 1 collagen (CTX1), cartilage oligomeric matrix protein (COMP) and calcium levels were determined. The data to be obtained as a result of our study can give information about the relationship between the skeletal and bone health of the athletes and anaerobic exercise.

NCT ID: NCT05110794 Active, not recruiting - Healthy Clinical Trials

A Multiple-Dose Study of LY3502970 in Healthy Participants

Start date: November 5, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.

NCT ID: NCT05075772 Active, not recruiting - Healthy Clinical Trials

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

A study in healthy man to investigate the absolute bioavailability of 100mg BI 765080, once administered as subcutaneous (SC) injection and once administered as intravenous infusion.

NCT ID: NCT05074134 Active, not recruiting - Healthy Clinical Trials

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

Start date: October 16, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single dose, Phase 1 study conducted at a single study center in the United States (USA). This study will evaluate the absorption, metabolism and elimination (AME), mass balance, safety and tolerability of a single dose of intravenously administered [14C]-TNP-2092. Healthy men aged 18 to 55, will be screened, and subjects who meet all eligibility criteria and provide written informed consent will be enrolled into the study within 28 days of Screening. Subjects will be admitted to the clinical unit on the day prior to dosing (Day -1). Subjects will fast overnight and then given a standard breakfast 30 min prior to dosing. Six subjects will be enrolled in the study and each will receive a single intravenous (IV) dose of 300 mg/3 ╬╝Ci [14C]-TNP-2092 administered over 60 minutes (±10 minutes).

NCT ID: NCT05027451 Active, not recruiting - Healthy Clinical Trials

Safety, Tolerability, and Pharmacokinetics of IXT-m200

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

Approximately 9 participants will be enrolled in the study in a single cohort. Participants will be randomized to 3 g IXT-m200 or placebo at 7:2. Each will receive their dose as a 30-min intravenous infusion, then remain at the study site overnight to complete Day 1 and Day 2 assessments (e.g., electrocardiogram (ECG), laboratory assessments, blood draws, and vital signs). Following discharge on Day 2, participants will return to the clinic for follow-up pharmacokinetic (PK) and safety assessments on Day 8, then every 1-3 weeks thereafter until Day 127.

NCT ID: NCT05012670 Active, not recruiting - Healthy Clinical Trials

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Start date: August 18, 2021
Phase: Phase 1
Study type: Interventional

Single-centre, open-label, non-randomised study to assess the mass balance recovery, PK, metabolite profile, and metabolite identification of a single oral dose of 14C labelled paxalisib ([14C] Paxalisib) in healthy male subjects.